In this study, we evaluated the combinatorial activity of the second generation mTOR inhibitor AZD2014 and of the type II JAK2 inhibitor BBT594 compared with allosteric mTOR inhibitor rapamycin and type I JAK2 inhibitor ruxolitinib in Ph-like ALL harboring CRLF2 rearrangement. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.